Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: Pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials

Drugs and Aging

Volumn 28, Issue 1, 2011, Pages 27-40

  Baraf, Herbert S B ^a   Gloth, F Michael ^b   Barthel, H Richard ^c   Gold, Morris S ^d   Altman, Roy D ^d  

^a Arthritis and Rheumatism Associates   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Novartis Consumer Health Inc ^*

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diclofenac, therapeutic use; Elderly; Nonsteroidal anti inflammatories, therapeutic use; Osteoarthritis, treatment; Topical

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DICLOFENAC SODIUM GEL; DRUG VEHICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYSIS OF VARIANCE; APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KELLGREN LAWRENCE GRADE; KNEE ARTHRITIS; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 78650702121     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11584880-000000000-00000     Document Type: Article

References (43)

1. Dawson J, Linsell L, Zondervan K, et al. Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology (Oxford) 2004 Apr; 43 (4): 497-504
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998 May; 41 (5): 778-99
3. Oliveria SA, Felson DT, Reed JI, et al. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995 Aug; 38 (8): 1134-41
4. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006 Feb; 20 (1): 3-25
5. Van Saase JLCM, van Romunde LKJ, Cats A, et al. Epidemiology of osteoarthritis: Zoetermeer survey: comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48: 271-80
6. Dillon CF, Rasch EK, Gu Q, et al. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-94. J Rheumatol 2006 Nov; 33 (11): 2271-9
7. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994 Mar; 84 (3): 351-8
8. McKenna MT, Michaud CM, Murray CJ, et al. Assessing the burden of disease in the United States using disability- adjusted life years. Am J Prev Med 2005 Jun; 28 (5): 415-23
9. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 Sep; 43 (9): 1905-15
10. American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview (IL): American Pain Society, 2003
11. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003 Dec; 62 (12): 1145-55
12. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007 Sep; 15 (9): 981-1000
13. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137-62
14. Evans JM, McMahon AD, McGilchrist MM, et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995 Jul 1; 311 (6996): 22-6
15. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991 Nov 15; 115 (10): 787-96
16. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006 Mar; 99 (3): 132-40
17. Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase- 2 inhibitors and traditional non-steroidal antiinflammatory drugs. Ann Med 2007; 39 (1): 18-27
18. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4-10; 364 (9450): 2021-9
19. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase- 2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun 3; 332 (7553): 1302-8
20. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use ofNSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf 2006; 29 (7): 621-32
21. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and antiinflammatory drugs - NSAIDs. Am J Ther 2004 Mar-Apr; 11 (2): 124-9
22. Evans JM, McGregor E, McMahon AD, et al. Nonsteroidal anti-inflammatory drugs and hospitalization for acute renal failure. Q J Med 1995 Aug; 88 (8): 551-7
23. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Jun 11; 330 (7504): 1366
24. Osteoarthritis: the care and management of osteoarthritis in adults. London: National Collaborating Centre for Chronic Conditions, 2008 Feb. Report no.: NICE clinical guideline 59
25. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57 (8): 1331-46
26. Kienzler J, GoldM,Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol NewDrugs 2010 Jan; 50: 50-61
27. Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Sep; 36 (9): 1991-9
28. Baraf HS, Gold M, Clark MB, et al. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial. Phys Sportsmed 2010; 38 (2): 19-28
29. Barthel HR, Haselwood D, Longley 3rd S, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum 2009 Dec; 39 (3): 203-12
30. Pham T, Van Der Heijde D, Lassere M, et al. Outcome variables for osteoarthritis clinical trials: the OMERACTOARSI set of responder criteria. J Rheumatol 2003 Jul; 30 (7): 1648-54
31. Bross IDJ. How to use ridit analysis. Biometrics 1958 Jun 15; 14: 18-38
32. ZhangW, DohertyM, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66 (3): 377-88
33. Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society - results from a workshop. Osteoarthritis Cartilage 1996 Dec; 4 (4): 217-43
34. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329 (7478): 1317-22
35. Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009 Apr 18; 143 (3): 238-45
36. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 2005; 6: 44
37. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial [see comment]. Arch Intern Med 2004 Oct 11; 164 (18): 2017-23
38. Baraf HSB, Gloth FM, Gold MS, et al. Efficacy of diclofenac sodium topical gel 1% in knee osteoarthritis of Kellgren-Lawrence grades 1, 2, or 3 severity [abstract]. J Gen Intern Med 2009; 24 (S1): S68
39. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006 Mar; 119 (3): 255-66
40. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21-27; 364 (9435): 665-74
41. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-55
42. Peniston JH, GoldMS, Clark MB, et al. An open-label longterm safety trial of diclofenac sodium 1% gel in patients with osteoarthritis of the knee. American Osteopathic Association 2009 Osteopathic Medical Conference & Exposition; 2009 Nov 1-5; New Orleans (LA)
43. Dawson J, Linsell L, Zondervan K, et al. Impact of persistent hip or knee pain on overall health status in elderly people: a longitudinal population study. Arthritis Rheum 2005 Jun 15; 53 (3): 368-74